My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

12.73 +0.60 (+4.95%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

October 03, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

September 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

September 22, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Recap: Enanta Pharmaceuticals Q3 Earnings ↗

August 08, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q3 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Analyst Ratings for Enanta Pharmaceuticals ↗

July 01, 2022

Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:

Via Benzinga

New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

September 07, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

September 01, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

August 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings for Enanta Pharmaceuticals ↗

June 01, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

August 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals ↗

August 01, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

August 01, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study ↗

July 29, 2022

Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants ↗

July 29, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a...

Via Benzinga

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

July 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗

June 28, 2022

Via Benzinga

Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid ↗

June 22, 2022

Another company says it invented the technology behind the pill first.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 ↗

July 06, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

June 21, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

June 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

June 02, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗

June 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint ↗

May 18, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...

Via Benzinga

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

May 18, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

10 Biggest Price Target Changes For Tuesday ↗

May 10, 2022

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.